|
(iii) 60,345 shares of common stock held by Biotechnology Value Trading Fund OS LP, or Trading Fund OS. BVF Partners OS Ltd, or Partners OS, as general partner of Trading Fund OS, may be
deemed to beneficially own 60,345 shares of common stock beneficially owned by Trading Fund OS. BVF Partners L.P., or Partners, as general partner of BVF, BVF II, the investment manager of Trading Fund OS, and the sole member of Partners OS, may be
deemed to beneficially own the 1,815,146 shares of common stock beneficially owned in the aggregate by BVF, BVF II, Trading Fund OS, and certain managed accounts of Partners, or the Partners Managed Accounts, including 51,988 shares of common stock
held in the Partners Managed Accounts. BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 1,815,146 shares of common stock owned by Partners. Mark N. Lampert is a director and officer of BVF Inc., and may be deemed
to beneficially own the 1,815,146 shares of common stock beneficially owned by BVF, Inc. Together, BVF, BVF II, Trading Fund OS, Partners OS, Partners, BVF Inc. and Mark N. Lampert (the BVF Entities) hold 2,220 shares of Series A
Convertible Preferred Stock (Series A Preferred) convertible for an aggregate of 2,220,000 shares of common stock. The Series A Preferred may not be converted if, after such conversion, the BVF Entities would beneficially own
more than 9.99% of the common stock then issued and outstanding (the Series A Blocker). As of December 31, 2018, the Series A Blocker limited the aggregate conversion of Series A Preferred to 972,000 of the 2,220,000
shares of common stock underlying the Series A Preferred. As a result of the Series A Blocker, included in the percentage of shares beneficially owned as of April 15, 2019 is the maximum number of shares of common stock issuable upon
conversion of Series A Preferred up to the limit imposed by the Series A Blocker, and excluded are the remaining shares of common stock issuable upon conversion of Series A Preferred that are prevented from converting due to the
Series A Blocker. Together the BVF Entities also hold 1,000 shares of Series B Convertible Preferred Stock (the Series B Preferred) convertible for an aggregate of 1,000,000 shares of common stock. The Series B
Preferred may not be converted if, after such conversion, the BVF Entities would beneficially own more than 9.99% of the common stock then issued and outstanding (the Series B Blocker). As of April 15, 2019, the Series B
Blocker limits the aggregate conversion of Series B Preferred by the BVF Entities to 0 out of the 1,000,000 shares of common stock underlying the Series B Preferred. Partners OS disclaims beneficial ownership of the shares of common stock
beneficially owned by Trading Fund OS. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the shares of common stock beneficially owned by BVF, BVF II, Trading Fund OS, and the Partners Management Accounts. The address
of the principal business and office of BVF Inc. and certain of its affiliates is 1 Sansome Street, 30th Floor, San Francisco, California, 94194. This information is based solely on a Schedule 13G/A filed with the SEC on
February 14, 2019, which reported ownership as of December 31, 2018.
|